Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a US-based, neuroscience-focused, biopharmaceutical company, announced on Wednesday that it has started its Phase one first-in-human clinical study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of investigational compound NBI-1117567 in healthy adult participants.

NBI-1117567, an investigational, oral, M1/M4 (M1 preferring) selective muscarinic agonist, is intended for the potential treatment of neurological and neuropsychiatric conditions.

Eiry W Roberts, M.D., Neurocrine Biosciences chief medical officer, said, 'Neurocrine Biosciences has the largest muscarinic portfolio in the industry, with compounds in development for psychiatric and neurological disorders. As an M1 preferring M1/M4 agonist, NBI-1117567 has the potential to treat symptoms of cognition in patients with neurological and neuropsychiatric conditions where psychosis might also be present.'

.

(C) 2024 M2 COMMUNICATIONS, source M2 PressWIRE